Compare Stocks → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BYSINASDAQ:FLXNNASDAQ:ONCTNASDAQ:SYRSNASDAQ:URGN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBYSIBeyondSpring$2.11+10.5%$2.35$0.65▼$4.00$74.35M0.14116,540 shs63,530 shsFLXNFlexion Therapeutics$9.12$9.20$4.30▼$13.66$458.93M1.531.18 million shsN/AONCTOncternal Therapeutics$8.55-3.5%$8.87$5.57▼$13.14$23.83M1.266,996 shs1,657 shsSYRSSyros Pharmaceuticals$4.99+9.9%$6.20$2.09▼$8.17$121.35M1.75272,041 shs151,952 shsURGNUroGen Pharma$14.37+4.7%$16.10$8.69▼$24.13$322.02M1.07340,056 shs278,571 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBYSIBeyondSpring+10.47%+19.89%-32.37%+134.97%+95.37%FLXNFlexion Therapeutics0.00%0.00%0.00%0.00%0.00%ONCTOncternal Therapeutics-3.50%-2.84%+4.01%+23.91%+30.34%SYRSSyros Pharmaceuticals+9.91%-6.73%-20.41%-23.23%+86.89%URGNUroGen Pharma+4.66%-4.83%-8.82%-4.90%+43.13%The system that called 2023’s top 7 stocks is at it again… (Ad)Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBYSIBeyondSpring0.005 of 5 stars0.00.00.00.00.02.50.0FLXNFlexion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AONCTOncternal Therapeutics2.3566 of 5 stars3.33.00.00.01.81.71.3SYRSSyros Pharmaceuticals3.9706 of 5 stars3.51.00.04.32.23.30.6URGNUroGen Pharma3.9562 of 5 stars3.51.00.04.51.93.30.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBYSIBeyondSpringN/AN/A$1.25-40.76% DownsideFLXNFlexion TherapeuticsN/AN/AN/AN/AONCTOncternal Therapeutics2.67Moderate Buy$31.33266.47% UpsideSYRSSyros Pharmaceuticals3.00Buy$14.33187.24% UpsideURGNUroGen Pharma3.00Buy$46.67224.75% UpsideCurrent Analyst RatingsLatest URGN, SYRS, BYSI, FLXN, and ONCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024URGNUroGen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.004/15/2024ONCTOncternal TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $28.004/4/2024URGNUroGen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.004/3/2024SYRSSyros PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$13.004/1/2024SYRSSyros PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.003/18/2024URGNUroGen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.003/15/2024URGNUroGen PharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$35.00 ➝ $34.001/29/2024ONCTOncternal TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBYSIBeyondSpring$1.35M60.83N/AN/A($0.36) per share-5.86FLXNFlexion Therapeutics$85.55M5.36N/AN/A($0.34) per share-26.82ONCTOncternal Therapeutics$790K29.11N/AN/A$10.19 per share0.84SYRSSyros Pharmaceuticals$9.94M13.42N/AN/A$0.79 per share6.32URGNUroGen Pharma$82.71M4.07N/AN/A($2.78) per share-5.17Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBYSIBeyondSpring-$33.28MN/A0.00∞N/AN/AN/AN/AN/AFLXNFlexion Therapeutics-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/AONCTOncternal Therapeutics-$39.48M-$13.51N/AN/AN/A-5,029.17%-95.87%-83.56%5/2/2024 (Estimated)SYRSSyros Pharmaceuticals-$164.57M-$5.76N/AN/AN/A-1,656.34%-227.91%-75.60%5/8/2024 (Estimated)URGNUroGen Pharma-$102.24M-$3.73N/AN/AN/A-123.61%N/A-70.48%5/9/2024 (Estimated)Latest URGN, SYRS, BYSI, FLXN, and ONCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023SYRSSyros Pharmaceuticals-$1.23-$1.19+$0.04-$0.20$2.40 million$0.39 million3/14/2024Q4 2023URGNUroGen Pharma-$0.67-$0.72-$0.05-$0.72$22.30 million$23.53 million 3/7/2024Q4 2023ONCTOncternal Therapeutics-$3.09-$3.11-$0.02-$3.11$0.17 million$0.30 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBYSIBeyondSpringN/AN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AN/AONCTOncternal TherapeuticsN/AN/AN/AN/AN/ASYRSSyros PharmaceuticalsN/AN/AN/AN/AN/AURGNUroGen PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBYSIBeyondSpringN/AN/AN/AFLXNFlexion TherapeuticsN/A4.384.05ONCTOncternal TherapeuticsN/A6.946.94SYRSSyros Pharmaceuticals2.073.953.95URGNUroGen PharmaN/A5.425.24OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBYSIBeyondSpring40.29%FLXNFlexion Therapeutics90.01%ONCTOncternal Therapeutics16.05%SYRSSyros Pharmaceuticals91.47%URGNUroGen Pharma91.29%Insider OwnershipCompanyInsider OwnershipBYSIBeyondSpring29.31%FLXNFlexion Therapeutics9.13%ONCTOncternal Therapeutics8.00%SYRSSyros Pharmaceuticals10.45%URGNUroGen Pharma11.13%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBYSIBeyondSpring7338.92 million27.52 millionOptionableFLXNFlexion Therapeutics25750.32 million45.73 millionOptionableONCTOncternal Therapeutics272.69 million2.47 millionOptionableSYRSSyros Pharmaceuticals6826.73 million23.94 millionOptionableURGNUroGen Pharma19823.45 million20.84 millionOptionableURGN, SYRS, BYSI, FLXN, and ONCT HeadlinesSourceHeadline125,226 Shares in UroGen Pharma Ltd. (NASDAQ:URGN) Acquired by Cerity Partners LLCmarketbeat.com - April 20 at 5:24 AMHC Wainwright Reiterates "Buy" Rating for UroGen Pharma (NASDAQ:URGN)americanbankingnews.com - April 20 at 4:32 AMBuy Rating Affirmed for Urogen Pharma Amid Promising Clinical Data and Strategic Conference Presentationsmarkets.businessinsider.com - April 18 at 12:39 PMUroGen Pharma (NASDAQ:URGN) Given "Buy" Rating at HC Wainwrightmarketbeat.com - April 18 at 8:23 AMUroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancersbusinesswire.com - April 17 at 12:02 PMUroGen's UGN-103 advances to Phase 3 for bladder cancerinvesting.com - April 16 at 10:43 PMUroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancerbusinesswire.com - April 15 at 8:00 AMUroGen Pharma Ltd.'s (NASDAQ:URGN) high institutional ownership speaks for itself as stock continues to impress, up 11% over last weekfinance.yahoo.com - April 14 at 1:17 PMUrogen Pharma’s Strategic Defense and Pipeline Progress Bolster Buy Ratingmarkets.businessinsider.com - April 4 at 3:29 PMUroGen Pharma (NASDAQ:URGN) Stock Rating Reaffirmed by HC Wainwrightmarketbeat.com - April 4 at 8:50 AMUroGen Pharma Ltd. (NASDAQ:URGN) Insider Sells $168,600.00 in Stockinsidertrades.com - March 22 at 6:30 AMUroGen: All Eyes On UGN-102seekingalpha.com - March 18 at 11:48 PMUroGen Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Linefinance.yahoo.com - March 17 at 5:45 PMUroGen Pharma Ltd. (NASDAQ:URGN) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 15 at 2:14 PMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Urogen Pharma (URGN) and Cullinan Management (CGEM)markets.businessinsider.com - March 14 at 11:32 PMUroGen Pharma Delivers Double Digit JELMYTO Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102finanznachrichten.de - March 14 at 6:32 PMUroGen Pharma Ltd (URGN) Reports Solid JELMYTO Growth Amidst Financial Challengesfinance.yahoo.com - March 14 at 1:26 PMURGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023investorplace.com - March 14 at 1:03 PMUrogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimateszacks.com - March 14 at 10:10 AMUroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102finance.yahoo.com - March 14 at 8:25 AMUroGen Pharma earnings preview: what to expectmarkets.businessinsider.com - March 13 at 12:58 PMUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com - March 8 at 8:00 AMUroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024finance.yahoo.com - March 4 at 9:33 AM3 Biotech Stocks Climbing the Ranks to Watchstocknews.com - March 1 at 12:11 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBeyondSpringNASDAQ:BYSIBeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.Flexion TherapeuticsNASDAQ:FLXNFlexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.Oncternal TherapeuticsNASDAQ:ONCTOncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.Syros PharmaceuticalsNASDAQ:SYRSSyros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.UroGen PharmaNASDAQ:URGNUroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.